Identifying Heart Failure Patients at High Risk of Mortality Using Biomarkers
Author Information
Author(s): Jankowska Ewa A., Filippatos Gerasimos S., von Haehling Stephan, Papassotiriou Jana, Morgenthaler Nils G., Cicoira Mariantonietta, Schefold Joerg C., Rozentryt Piotr, Ponikowska Beata, Doehner Wolfram, Banasiak Waldemar, Hartmann Oliver, Struck Joachim, Bergmann Andreas, Anker Stefan D., Ponikowski Piotr
Primary Institution: Department of Heart Diseases, Wroclaw Military Hospital, Wroclaw, Poland
Hypothesis
Assessment of plasma C-terminal pro-endothelin-1 (CT-proET-1) is of prognostic value in patients with chronic heart failure (CHF), beyond other prognosticators.
Conclusion
Plasma CT-proET-1 is a novel predictor of increased 12-month cardiovascular mortality in patients with CHF.
Supporting Evidence
- Increasing CT-proET-1 was a predictor of increased cardiovascular mortality at 12-months of follow-up.
- Patients with high plasma CT-proET-1 had particularly high plasma NT-proBNP.
- Adding CT-proET-1 to the base model had stronger prognostic power than adding NT-proBNP.
Takeaway
Doctors can use a blood test for a specific protein to help figure out which heart failure patients are at a higher risk of dying within a year.
Methodology
The study examined 491 patients with systolic CHF, measuring plasma CT-proET-1 using a chemiluminescence immunoassay and following them for 12 months.
Potential Biases
Potential bias due to the involvement of a biotech company in data collection and analysis.
Limitations
The study population was predominantly male, and the small number of patients in NYHA class I may limit generalizability.
Participant Demographics
491 patients, average age 63 years, 91% men, with varying NYHA class and ischemic etiology.
Statistical Information
P-Value
p=0.03
Confidence Interval
95% CI 1.04–1.95
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website